ABT

ABBOTT LABORATORIES

Healthcare • USA

Apr 05 • 04:00PM ET
134.80
+1.45 (+1.09%)
Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vesti ... read more

Full Time Employees 114,000
Phone 224 667 6100
Website https://www.abbott.com
CEO Mr. Robert B. Ford
IPO Date 1980-03-17
Sector Healthcare
Industry Medical - Devices
Address 100 Abbott Park Road, North Chicago, IL 60064-6400
Balance Sheet
Total Cash $6,532,000,000
Total Debt $13,242,000,000
Current Ratio 1.78
Quick Ratio 1.09
Profitability
Gross Margin 55.81%
Net Margin 31.89%
ROE 27.52%
ROA 16.58%
ROIC 21.01%
Balance Sheet
Total Cash $6,532,000,000
Total Debt $13,242,000,000
Current Ratio 1.78
Quick Ratio 1.09
Profitability
Gross Margin 55.81%
Net Margin 31.89%
ROE 27.52%
ROA 16.58%
ROIC 21.01%
Name ABBOTT LABORATORIES Sector Healthcare Currency USD Relative Volume 1.55 Market Cap 215819
Current Ratio 1.67 Dividend / Share 2.2 EPS 7.64 Revenue 41950000000 P/S 5.1
P/E 16.1 Beta 0.11 Income 13402000000 Volume 10765409 Average Volume 6943888
Distance to 200DMA 6.3% 200 DMA 117.06 50 DMA 131.06 ROA 17.8 ROE 32.2
Distance to 50DMA -5.05% Return 1Y 14.13% Return YTD 10.6% Forward PE Qtly Growth YOY
Debt/Eq 0.7 P/B 4.5 Dividend Yield 1.9% Net Margin 31.95% Payout Ratio 28.7
Performance
52 Week Range 28.7%
Distance to 200DMA 0.41%
Day Change Percent $0.55
Performance Week $0.55
Performance Month $0.55
Performance Quarter 2024-07-15
Performance YTD $0.55
Performance Year $0.55

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $7,558,000,000
Total Debt $14,979,000,000
Current Ratio 1.60%
Quick Ratio 0.98%
Profitability
Gross Margin 55.81%
Net Margin 31.89%
ROE 27.52%
ROA 16.58%
ROIC 21.01%
Valuation
Price to Earnings 17.36
Price to Book 4.78
Price to Sales 5.54
Price to Free Cash Flow 35.22
Dividends
Payout Ratio 28.85%
Dividend Yield 1.66%
Dividend Amount $0.55
Last Dividend Pay Date 2024-07-15
Last Dividend Paid $0.55
Performance
52 Week Range 28.7%
Distance to 200DMA 0.41%
Day Change Percent $0.55
Performance Week $0.55
Performance Month $0.55
Performance Quarter 2024-07-15
Performance YTD $0.55
Performance Year $0.55
Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vesti ... read more

Full Time Employees 114,000
Phone 224 667 6100
Website https://www.abbott.com
CEO Mr. Robert B. Ford
IPO Date 1980-03-17
Sector Healthcare
Address 100 Abbott Park Road, North Chicago, IL 60064-6400
Histogram - Daily

Balance Sheet
Total Cash $7,558,000,000
Total Debt $14,979,000,000
Current Ratio 1.60%
Quick Ratio 0.98%
Profitability
Gross Margin 0.5560%
Net Margin 0.1400%
ROE 0.15%
ROA 0.08%
Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vesti ... read more

Full Time Employees 114,000
Phone 224 667 6100
Website https://www.abbott.com
CEO Mr. Robert B. Ford
IPO Date 1980-03-17
Sector Healthcare
Address 100 Abbott Park Road, North Chicago, IL 60064-6400
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

3 Magnificent Stocks That Are Passive Income Machines
3 Magnificent Stocks That Are Passive Income Machines

Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.

2025-05-17 06:40:00 - fool.com
Abbott India's quarterly profit climbs 28% on strong demand
Abbott India's quarterly profit climbs 28% on strong demand

Drugmaker Abbott India reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

2025-05-15 10:12:39 - reuters.com
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with R

New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is link

2025-05-15 09:05:00 - prnewswire.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on I

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

2025-05-07 10:00:54 - zacks.com
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio?
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfoli

Investing in excellent dividend stocks can be a great strategy to mitigate risk and boost long-term returns. Companies that can dispense regular payouts to their shareholders -- especially those that

2025-05-03 08:20:00 - fool.com
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test f

The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concuss

2025-05-01 09:00:00 - prnewswire.com
3 Dividend Stocks to Buy and Hold for the Next Decade
3 Dividend Stocks to Buy and Hold for the Next Decade

Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.

2025-04-28 07:47:00 - fool.com
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also b

2025-04-27 14:15:00 - prnewswire.com
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE

2025-04-26 19:15:00 - prnewswire.com
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?

With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.

2025-04-25 16:00:51 - zacks.com